ANAPTYSBIO, INC. (NASDAQ:ANAB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers
On February24, 2017, the Compensation Committee (the Committee)
of the Board of Directors (the Board) of AnaptysBio, Inc. (the
Company) approved the 2016 annual bonuses for Hamza Suria, Marco
Londei and Matthew Moyle, the Companys named executive officers.
The named executive officers other compensation for 2016 was
previously reported by the Company in the 2016 Summary
Compensation Table included in the Companys prospectus, dated
January26, 2017 (the Prospectus), filed with the Securities and
Exchange Commission under Rule 424(b) of the Securities Act of
1933, as amended, relating to the Companys registration statement
on Form S-1, as amended (Registration No.333-206849). As of the date
of the Prospectus, the 2016 bonuses for the named executive
officers had not been determined and, therefore, were not
included in the 2016 Summary Compensation Table. Below is a
revised 2016 Summary Compensation Table, which includes the
bonuses paid to the named executive officers and revised total
compensation figures for 2016:
|Fiscal Year||Salary||Bonus||Option Awards(1)||All Other Compensation||Total|
Hamza Suria, M.B.A.
President and Chief Executive Officer
Matthew Moyle, Ph.D.(2)
Chief Scientific Officer
Marco Londei, M.D.
Chief Medical Officer
The amounts reported in this column represent the aggregate
grant-date fair value of the awards granted under our 2006
Equity Incentive Plan to our named executive officers during
the years ended December31, 2015 and 2016, as computed in
accordance with FASB ASC Topic 718. The assumptions used in
calculating the grant date fair value of the awards reported
in the Stock Option Awards column are set forth in Note 8 to
the consolidated financial statements in the prospectus for
our initial public offering, filed with the U.S. Securities
and Exchange Commission (SEC) on January26, 2017. Note that
the amounts reported in this column reflect the aggregate
accounting cost for these awards, and do not necessarily
correspond to the actual economic value that may be received
by the named executive officers from the awards.
Reflects Dr.Moyles salary and bonus from the commencement of
his employment on May16, 2016, through December31, 2016.
Reflects group term life insurance premiums paid by us on
behalf of Mr.Suria.
Reflects reimbursements paid to, or on behalf of, Dr.Moyle
during the year ended December31, 2016, consisting of $36,221
for temporary housing and moving expenses and $1,505 for
group term life insurance premiums paid by us on behalf of
Reflects reimbursements paid to, or on behalf of Dr.Londei
during the year ended December31, 2016, consisting of $7,984
for moving expenses and $3,960 for group term life insurance
premiums paid by us on behalf of Dr.Londei.
Reflects reimbursements paid to, or on behalf of, Dr.Londei
during the year ended December31, 2015, consisting of $39,462
for temporary housing and moving expenses, including tax
respect to temporary housing payments, and $2,580 for group
term life insurance premiums paid by us on behalf of
About ANAPTYSBIO, INC. (NASDAQ:ANAB)
AnaptysBio, Inc. is a United States-based clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. Its pipeline includes ANB020 and ANB019. It is advancing its ANB020 product candidate, an antibody that inhibits the activity of interleukin-33, for the treatment of severe adult asthma and severe adult peanut allergy. In addition, it is also developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis and palmoplantar pustular psoriasis. It is also developing a portfolio of checkpoint receptor agonist antibodies designed for the treatment of human autoimmune diseases. The Company develops its product candidates using its antibody discovery technology platform. It has completed a Phase I trial of ANB020 in healthy volunteers in Australia. ANAPTYSBIO, INC. (NASDAQ:ANAB) Recent Trading Information
ANAPTYSBIO, INC. (NASDAQ:ANAB) closed its last trading session down -0.78 at 23.07 with 95,492 shares trading hands.